TINGSN

Jiangsu TINGSN Technology Co., Ltd., primarily operates in the health and medical field. On January 23, 2019, it officially launched the research and development of innovative interventional treatment products for cardiac arrhythmia and a cardiac 3D mapping system. The company relies on the national key laboratory of Nanjing University and Purdue University in the United States, hiring several professors from various fields as R&D consultants. Led by a postdoctoral fellow from Purdue University, the R&D team has achieved independent innovation in catheter positioning within the heart and software algorithms. The 3D mapping system currently under development aims to reduce the cost of surgical instruments, lower the cost of such surgeries, and alleviate the financial burden on patients' families and health insurance. This will allow more than 7,000 county-level hospitals in China to truly provide localized cardiac interventional surgery services, increasing the application rate of surgeries and benefiting numerous patients. The company strives to break the current technological and product monopoly held by foreign companies in the Chinese market, enhancing the technological value and self-reliance of domestically produced medical devices. The company currently holds 9 patents, including 8 invention patents and 1 utility model patent. It has also developed the first learning tool app in China specifically for "cardiac electrophysiology" and is simultaneously developing the first PC-based surgical simulator app in China based on a digital heart model and VR virtual simulation operations. These apps and simulators are mainly used for doctors and students to experience and practice real-life scenarios of heart surgeries online, accelerating the mastery of professional skills. They aim to fill the gap in the study and practice of cardiac interventional surgeries for medical students and doctors. "TINGSN, using technology to safeguard health" is the dream pursued by all TINGSN employees. TINGSN persists in independent scientific and technological innovation, applying cutting-edge technology to its products to narrow the competitive gap with international brands. It gradually realizes the aspiration of substituting imported interventional treatment products and vigorously markets its products overseas, striving to achieve the dream of creating a national brand of "good products made in China."